For research use only. Not for therapeutic Use.
Baxdrostat (Cat No.: I023000) is an investigational, oral selective aldosterone synthase (CYP11B2) inhibitor developed for the treatment of resistant and uncontrolled hypertension. By specifically targeting aldosterone synthesis without significantly affecting cortisol production, baxdrostat reduces sodium retention and blood pressure while minimizing side effects associated with non-selective mineralocorticoid pathway inhibition. It offers a novel mechanism of action for patients who do not respond adequately to standard antihypertensive therapies. Baxdrostat is currently being evaluated in clinical trials and shows promise as a targeted treatment for cardiovascular and renal conditions.
| CAS Number | 1428652-17-8 |
| Synonyms | N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide |
| Molecular Formula | C22H25N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1 |
| InChIKey | VDEUDSRUMNAXJG-LJQANCHMSA-N |
| SMILES | CCC(=O)NC1CCCC2=C1C=NC=C2C3=CC4=C(C=C3)N(C(=O)CC4)C |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN) |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
